Hyperfine (HYPR) AI Stock Analysis

• Market Cap: $59.55M
• Dividend Yield: N/A
• Average Volume (3M): 4.24M
• Price to Earnings (P/E): ―
• Beta (1Y): 1.31
• Revenue Growth: 0.34%
• EPS Growth: 6.20%
• Country: US
• Employees: 111
• Sector: Healthcare
• Sector Strength: 39
• Industry: Medical - Devices
• EPS (TTM): -0.12
• Shares Outstanding: 62,784,560
• 10 Day Avg. Volume: 220,381
• 30 Day Avg. Volume: 4,242,890
• PEG Ratio: -0.07
• Price to Book (P/B): 0.48
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -0.81
• Enterprise Value/Market Cap: -0.98
• Enterprise Value/Revenue: -1.17
• Enterprise Value/Gross Profit: -10.76
• Enterprise Value/Ebitda: 0.34
• 1Y Price Target: $0.92
• Price Target Upside: 17.95% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 4

• Rating: 52 Neutral
• Price Target: $1.00 ▲(28.21%Upside)

Hyperfine's overall stock score reflects a company in transition. Strong revenue growth and a solid equity position are overshadowed by significant profitability challenges and negative cash flows. Technical analysis suggests mixed short-term momentum, while valuation metrics highlight the risks associated with ongoing losses. The earnings call provides some optimism for future growth through diversification and expansion, but the cautious outlook tempers enthusiasm.

Positive Factors

Market Expansion

The sales pipeline is solid, with two new indications (Alzheimer’s, Stroke) set to expand the total addressable market from $1.5 billion to over $6 billion.

Regulatory Approvals

Significant enhancements to imaging quality have been achieved through nine FDA clearances since 2020.

Technology and Innovation

HYPR is partnering with NVIDIA to develop future technologies that incorporate NVIDIA's advanced artificial intelligence (AI) capabilities with the Swoop system.

Negative Factors

Sales and Revenue

HYPR reported Q1 results that missed estimates on the top line, with revenue of $2.1M missing both consensus and estimates by ~$0.7M.

Sales Cycle Challenges

HYPR is seeing an elongation in their selling cycle of up to ~18 months due to ongoing softness in the hospital capital environment.

Hyperfine Business Overview & Revenue Model

Company Description

Hyperfine (HYPR) is a pioneering company in the medical technology sector, specializing in the development and commercialization of portable and affordable MRI systems. The company's flagship product, Swoop, is a point-of-care MRI system designed to improve accessibility to MRI imaging by being easy to use and deployable in various medical settings, including emergency departments and rural healthcare facilities.

How the Company Makes Money

Hyperfine generates revenue primarily through the sale and leasing of its Swoop portable MRI systems. The company also earns income from service contracts, offering maintenance and technical support for their equipment. Additional revenue streams may include training services for medical staff and software updates for the MRI systems. Significant partnerships with healthcare providers and research institutions further enhance its market reach and adoption of its innovative MRI technology.

Hyperfine Financial Statement Overview

Summary

Hyperfine shows strong revenue growth and a solid equity position with no debt. However, the company faces significant profitability challenges with continuous net losses and negative cash flows. The high equity ratio and lack of debt provide stability, but the negative ROE and cash flow issues indicate a need for improved operational efficiency.

Income Statement

Hyperfine's income statement shows significant revenue growth over the years, with the latest revenue of $12.89 million compared to $0.29 million in 2020. However, the company continues to operate at a loss, with a net loss of $40.72 million for 2024. The gross profit margin has improved to 45.7% in 2024 from a negative margin in earlier years, but net profit margins remain substantially negative. The EBIT and EBITDA margins are also deeply negative, indicating ongoing operational challenges. The revenue growth is a positive sign, but the persistent losses are a major concern.

Balance Sheet

The balance sheet of Hyperfine shows a relatively strong equity position with stockholders' equity at $49.04 million by the end of 2024. The company has no debt, resulting in a debt-to-equity ratio of 0, which is a positive aspect. However, the return on equity is negative due to significant net losses. The equity ratio stands at 83.2%, indicating a strong capital structure. The absence of debt and a high equity ratio are strengths, yet the negative ROE reflects profitability challenges.

Cash Flow

Hyperfine's cash flow statement reveals negative free cash flow, with a free cash flow of -$39.15 million in 2024. Operating cash flow exceeds net income, suggesting decent cash conversion efficiency, but both metrics are negative. The company has been investing less over time, which may impact future growth prospects. While the company has managed to finance operations without debt, the continuous negative cash flows pose a risk to long-term sustainability.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	11.73M	12.89M	11.03M	6.81M	1.50M	294.00K
Gross Profit	5.42M	5.89M	4.76M	907.00K	-1.17M	-477.00K
EBITDA	-42.73M	-42.22M	-47.06M	-72.86M	-64.14M	-23.20M
Net Income	-40.29M	-40.72M	-44.24M	-72.45M	-64.83M	-23.36M
Balance Sheet
Total Assets	53.38M	58.90M	94.20M	134.05M	202.47M	71.53M
Cash, Cash Equivalents and Short-Term Investments	33.09M	37.65M	75.18M	117.47M	188.50M	62.68M
Total Debt	0.00	269.00K	185.00K	0.00	0.00	178.00K
Total Liabilities	10.26M	9.86M	9.80M	10.33M	16.25M	132.58M
Stockholders Equity	43.11M	49.04M	84.40M	123.72M	186.23M	-61.05M
Cash Flow
Free Cash Flow	-36.22M	-39.15M	-42.61M	-72.92M	-49.89M	-23.09M
Operating Cash Flow	-35.51M	-38.77M	-41.81M	-72.34M	-47.18M	-21.52M
Investing Cash Flow	-710.00K	-383.00K	-804.00K	-585.00K	-2.71M	-1.57M
Financing Cash Flow	6.55M	1.02M	174.00K	7.00K	176.77M	60.94M

Hyperfine Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 0.78
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HYPR, the sentiment is Positive. The current price of 0.78 is above the 20-day moving average (MA) of 0.74, above the 50-day MA of 0.71, and below the 200-day MA of 0.90, indicating a neutral trend. The MACD of 0.02 indicates Negative momentum. The RSI at 56.99 is Neutral, neither overbought nor oversold. The STOCH value of 66.78 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for HYPR.

Hyperfine Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
ICAD	60 Neutral	$101.92M	―	-16.53%	―	-4.15%	3.49%
TELA	60 Neutral	$76.34M	―	-267.29%	―	12.78%	15.53%
HYPR	52 Neutral	$59.55M	―	-67.86%	―	0.34%	6.20%
MRSN	47 Neutral	$37.93M	―	-505.14%	―	-11.21%	47.20%
Sector *	46 Neutral	C$194.90M	-3.46	-23.22%	2.62%	21.17%	-0.58%
KZR	42 Neutral	$33.24M	―	-57.78%	―	-100.00%	18.17%
RBOT	39 Underperform	$45.80M	―	-104.36%	―	―	-1455.58%

Hyperfine Corporate Events

Hyperfine Chairperson R. Scott Huennekens Resigns

On May 21, 2025, R. Scott Huennekens, Chairperson of Hyperfine, Inc.’s Board of Directors, announced his resignation effective May 22, 2025, due to personal reasons and other commitments. His departure was not due to any disagreements with the company. The Board expressed gratitude for his service since 2021 and, in response, reduced its size from six to five members. Daniel J. Wolterman, a current board member, was appointed as the new Chairperson, and the company anticipates his leadership.

The most recent analyst rating on (HYPR) stock is a Buy with a $1.50 price target. To see the full list of analyst forecasts on Hyperfine stock, see the HYPR Stock Forecast page.

Hyperfine Holds Annual Stockholders Meeting

On May 19, 2025, Hyperfine, Inc. held its annual meeting of stockholders, where approximately 90.95% of the voting power was represented. During the meeting, all board nominees were reelected, and Grant Thornton LLP was ratified as the independent registered public accounting firm for the fiscal year ending December 31, 2025.

The most recent analyst rating on (HYPR) stock is a Buy with a $1.50 price target. To see the full list of analyst forecasts on Hyperfine stock, see the HYPR Stock Forecast page.